Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gliclazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gliclazide SCHEMBL1537023 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3GAAKDM4E | |
| Gliclazide SCHEMBL291434 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3GAAKDM4E | |
| Gliclazide SCHEMBL16387 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3GAAKDM4E | |
| Gliclazide SCHEMBL239075 | 0.84 | ALDH1A1 (0.97) | ALDH1A1LMNAAKR1C3GAAKDM4E | |
| Gliclazide SCHEMBL6344915 | 0.80 | ALDH1A1 (0.88) | ALDH1A1LMNAAKR1C3GAAKDM4E | |
| Gliclazide SCHEMBL30011556 | 0.79 | ALDH1A1 (0.86) | ALDH1A1LMNAAKR1C3GAAKDM4E | |
| Gliclazide SCHEMBL6679802 | 0.79 | ALDH1A1 (0.80) | ALDH1A1LMNAAKR1C3GAAKDM4E | |
| SCHEMBL17309638 | 0.76 | ALDH1A1 (0.76) | ALDH1A1LMNAAKR1C3GAAKDM4E | |
| Gliclazide SCHEMBL1967443 | 0.75 | ALDH1A1 (0.77) | ALDH1A1LMNAAKR1C3GAAKDM4E | |
| Tolbutamide SCHEMBL16931015 | 0.73 | ALDH1A1 (0.70) | ALDH1A1LMNACYP3A4MAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115932110-A | Rapid method for determining concentration of metformin and gliclazide in human plasma by adopting phospholipid removing plate and liquid chromatography-mass spectrometry | 合肥市开凡检测科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| EP-3666267-B1 | COMBINATION PRODUCT CONTAINING A LIMONOID COMPOUND AND METFORMIN | ZHEJIANG YANGSHENGTANG INST OF NATURAL MEDICATION CO LTD (CN) | 2023-11-15 | — | — | EP | disclosed |
| US-11679097-B2 | Combination product containing limonoid compound and biguanide compound | ZHEJIANG YANGSHENGTANG INSTITUTE OF NATURAL MEDICATION CO., LTD. (CN) | 2023-06-20 | — | — | US | disclosed |
| CN-115932110-A | Rapid method for determining concentration of metformin and gliclazide in human plasma by adopting phospholipid removing plate and liquid chromatography-mass spectrometry | 合肥市开凡检测科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-109381471-B | Combination product comprising limonoids and biguanides | 浙江养生堂天然药物研究所有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220125757-A1 | COMBINATION PRODUCT CONTAINING LIMONOID COMPOUND AND BIGUANIDE COMPOUND | ZHEJIANG YANGSHENGTANG INSTITUTE OF NATURAL MEDICATION CO., LTD. (CN) | 2022-04-28 | — | — | US | disclosed |
| EP-3666267-A1 | COMPOSITE PRODUCT CONTAINING LIMONIN COMPOUND AND BIGUANIDE COMPOUND | Zhejiang Yangshengtang Institute Of Natural Medication Co., Ltd. (CN) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125757-A1 | COMBINATION PRODUCT CONTAINING LIMONOID COMPOUND AND BIGUANIDE COMPOUND | LIMK1, LIMK2, SLC5A2 | ALDH1A1 2950/4885LMNA 243/4885AKR1C3 1300/4885 |
| US-11679097-B2 | Combination product containing limonoid compound and biguanide compound | LIMK1, LIMK2, SLC5A2 | ALDH1A1 2950/4885LMNA 243/4885AKR1C3 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.